Effect of vitamin D on anxiety and depresion of patients with colorectal cancer
Phase 2
Recruiting
- Conditions
- Condition 1: Anxiety. Condition 2: Depression.Anxiety disorder, unspecifiedF32.9Major depressive disorder, single episode, unspecifiedF41.9
- Registration Number
- IRCT20220609055113N1
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Ability to read and write in Persian
Ability to answer questionnaire questions
Exclusion Criteria
Complicated diabetes or hypertension
History of visiting a psychiatrist or psychologist in the last 6 months or taking psychotropic drugs in the last 6 months
Pregnancy
Breastfeeding
Taking vitamin D or vitamin D3 analogs in the last 3 months
Vitamin D serum level more than 100 ng/ml
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Depression score in Zung questionnaire. Timepoint: Before starting intervention, 90 days after starting to take cholecalciferol. Method of measurement: Zung Self-Rating Depression Scale questionnaire.;Anxiety score in Zung questionnaire. Timepoint: Before starting intervention, 90 days after starting to take cholecalciferol. Method of measurement: Zung Self-Rating Depression Scale qestionnaire.;Serum level of 25-hydroxy vitamin D3. Timepoint: Before starting the intervention and 90 days after starting cholecalciferol. Method of measurement: enzyme-linked immunosorbent assay.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways mediate vitamin D's impact on anxiety and depression in colorectal adenocarcinoma patients (IRCT20220609055113N1)?
How does vitamin D supplementation compare to SSRIs in managing F32.9 and F41.9 symptoms in colorectal cancer patients?
Which serum biomarkers correlate with vitamin D efficacy in IRCT20220609055113N1 colorectal cancer anxiety/depression trial?
What adverse events are associated with high-dose vitamin D in phase II colorectal cancer trials targeting mood disorders?
Are there synergistic effects of combining vitamin D with omega-3 fatty acids for treating anxiety in RAS mutant colorectal adenocarcinoma?